Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy

Non–Small Cell Lung Cancer, Version 1.2015

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Gregory A. Masters et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung Cancer

(2013) Satoshi Igawa et al.   CHEMOTHERAPY

A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901

(2013) T. Harada et al.   ONCOLOGIST

Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401)

(2010) Hiroyasu Kaneda et al.   Journal of Thoracic Oncology

Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer

(2009) Tsuneo Shimokawa et al.   International Journal of Clinical Oncology

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer

(2009) Kyoichi Kaira et al.   LUNG CANCER